Business Description
Virax Biolabs Group Ltd
ISIN : KYG9495L1251
Share Class Description:
VRAX: Class ADescription
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.17 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.46 | |||||
| Beneish M-Score | 11.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -10.6 | |||||
| 3-Year EBITDA Growth Rate | -79.9 | |||||
| 3-Year EPS without NRI Growth Rate | -76.9 | |||||
| 3-Year FCF Growth Rate | -92.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.41 | |||||
| 9-Day RSI | 54.8 | |||||
| 14-Day RSI | 55.17 | |||||
| 6-1 Month Momentum % | 66.06 | |||||
| 12-1 Month Momentum % | 56.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.57 | |||||
| Quick Ratio | 11.39 | |||||
| Cash Ratio | 10.5 | |||||
| Days Inventory | 500.98 | |||||
| Days Sales Outstanding | 8.59 | |||||
| Days Payable | 1369.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.3 | |||||
| Shareholder Yield % | -50.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40 | |||||
| Operating Margin % | -7387.06 | |||||
| Net Margin % | -7741.18 | |||||
| FCF Margin % | -6207.06 | |||||
| ROE % | -97.03 | |||||
| ROA % | -89.92 | |||||
| ROIC % | -379.77 | |||||
| ROC (Joel Greenblatt) % | -538.1 | |||||
| ROCE % | -98.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 63.68 | |||||
| PB Ratio | 1.22 | |||||
| Price-to-Tangible-Book | 1.22 | |||||
| EV-to-EBIT | -0.51 | |||||
| EV-to-EBITDA | -0.52 | |||||
| EV-to-Revenue | 39.69 | |||||
| EV-to-FCF | -0.64 | |||||
| Price-to-Net-Current-Asset-Value | 1.45 | |||||
| Price-to-Net-Cash | 1.62 | |||||
| Earnings Yield (Greenblatt) % | -196.08 | |||||
| FCF Yield % | -50.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Virax Biolabs Group Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.085 | ||
| EPS (TTM) ($) | -2.61 | ||
| Beta | 0 | ||
| Volatility % | 302.62 | ||
| 14-Day RSI | 55.17 | ||
| 14-Day ATR ($) | 0.335899 | ||
| 20-Day SMA ($) | 2.1235 | ||
| 12-1 Month Momentum % | 56.03 | ||
| 52-Week Range ($) | 0.6 - 8.9999 | ||
| Shares Outstanding (Mil) | 4.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Virax Biolabs Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Virax Biolabs Group Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Virax Biolabs Group Ltd Frequently Asked Questions
What is Virax Biolabs Group Ltd(VRAX)'s stock price today?
The current price of VRAX is $2.42. The 52 week high of VRAX is $9.00 and 52 week low is $0.60.
When is next earnings date of Virax Biolabs Group Ltd(VRAX)?
The next earnings date of Virax Biolabs Group Ltd(VRAX) is .
Does Virax Biolabs Group Ltd(VRAX) pay dividends? If so, how much?
Virax Biolabs Group Ltd(VRAX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers